Layered inorganic nanocomposites: A promising carrier for 5-fluorouracil (5-FU)

被引:83
|
作者
Kevadiya, Bhavesh D. [1 ,4 ]
Patel, Tapan A. [2 ]
Jhala, Devendrasinh D. [2 ]
Thumbar, Rahul P. [3 ]
Brahmbhatt, Harshad [1 ]
Pandya, Maharshi P. [4 ]
Rajkumar, Shalini [4 ]
Jena, Prasant K. [4 ]
Joshi, Ghanshyam V. [1 ]
Gadhia, Pankaj K. [3 ]
Tripathi, C. B. [5 ]
Bajaj, Hari C. [1 ]
机构
[1] CSIR, Discipline Inorgan Mat & Catalysis, Cent Salt & Marine Chem Res Inst, Bhavnagar 364021, Gujarat, India
[2] Gujarat Univ, Dept Zool, Univ Sch Sci, Ahmadabad, Gujarat, India
[3] Veer Narmad S Gujarat Univ, Dept Biosci, Surat, Gujarat, India
[4] Nirma Univ, Inst Sci, Ahmadabad, Gujarat, India
[5] Govt Med Coll, Dept Pharmacol, Bhavnagar, Gujarat, India
关键词
Nanocomposites; Intercalation; Na+-clay; Controlled drug release; Genotoxicity; ADVANCED COLORECTAL-CANCER; DNA-DAMAGE; RELEASE; FLUOROURACIL; DELIVERY; THERAPY; MONTMORILLONITE; NANOPARTICLES; MECHANISMS;
D O I
10.1016/j.ejpb.2012.01.004
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
We report here the intercalation of 5-fluorouracil (5-FU), an anticancer drug in interlayer gallery of Na+ clay (Montmorillonite, MMT), with the assistance of biopolymer (chitosan, CS). The X-ray diffraction patterns, thermal and spectroscopic analyses indicated the drug intercalation into the clay interlayer space in support of CS and stabilized in the longitudinal monolayer by electrostatic interaction. In vitro drug release showed controlled release pattern. The genotoxic effect of drug was in vitro evaluated in human lymphocyte cell culture by comet assay, and results indicated significant reduction in DNA damage when drug was intercalated with clay and formulated in composites. The results of in vitro cell viability assay in cancer cells pointed at decreased toxicity of drug when encapsulated in Na+-clay plates than the pristine drug. In vivo pharmacokinetics, biodistribution, hepatotoxicity markers, e.g., SGPT and SGOT, and liver/testicular histology in rats showed plasma/tissue drug levels were within therapeutic window as compared to pristine drug. Therefore, drug-clay hybrid and composites can be of considerable value in chemotherapy of cancer with reduced side effects. (C) 2012 Elsevier B.V. All rights reserved.
引用
收藏
页码:91 / 101
页数:11
相关论文
共 50 条
  • [41] COMPARISON OF TREATMENT OF METASTATIC GASTROINTESTINAL CANCER WITH 5-FLUOROURACIL (5-FU) TO A COMBINATION OF 5-FU WITH CYTOSINE-ARABINOSIDE
    GAILANI, S
    HOLLAND, JF
    BURNINGHAM, R
    LEONE, L
    LARSEN, V
    FALKSON, G
    CANCER, 1972, 29 (05) : 1308 - +
  • [42] 1-alkylcarbonyloxymethyl prodrugs of 5-fluorouracil (5-FU): Synthesis, physicochemical properties, and topical delivery of 5-FU
    Taylor, HE
    Sloan, KB
    JOURNAL OF PHARMACEUTICAL SCIENCES, 1998, 87 (01) : 15 - 20
  • [43] Methotrexate (MTX) and 5-fluorouracil (5-FU) in advanced colorectal cancer patients previously treated with adjuvant 5-FU
    Pronzato, P
    Vaira, F
    Viganni, A
    Losardo, P
    Bertelli, G
    EUROPEAN JOURNAL OF CANCER, 1995, 31A : 760 - 760
  • [44] Intraoperative 5-fluorouracil (5-FU) with postoperative 5-FU injections versus postoperative injections only in primary trabeculectomies
    Urken, SI
    Skuta, GL
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 1996, 37 (03) : 117 - 117
  • [45] 5-FLUOROURACIL (5-FU) COMBINED WITH LEUCOVORIN (LV) IN PATIENTS WITH ADVANCED 5-FU RESISTANT COLORECTAL-CANCER
    VANGROENINGEN, CJ
    PETERS, GJ
    PINEDO, HM
    PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, 1988, 29 : 202 - 202
  • [46] Topical delivery of 5-fluorouracil (5-FU) by 1,3-bisalkylcarbonyl-5-FU prodrugs
    Beall, HD
    Sloan, KB
    INTERNATIONAL JOURNAL OF PHARMACEUTICS, 2002, 231 (01) : 43 - 49
  • [47] Preoperative chemoradiotherapy with 5-fluorouracil (5-FU) or 5-FU/oxaliplatin (5FU/OX) for rectal cancer is a feasible treatment strategy in the elderly
    Dolinsky, C. M.
    Mahmoud, N. N.
    Mick, R.
    Sun, W.
    Whittington, R.
    Solin, L. J.
    Haller, D. G.
    O'Dwyer, P.
    Fry, R. D.
    Metz, J. M.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2006, 66 (03): : S308 - S308
  • [48] TREATMENT OF CONDYLOMA ACUMINATA WITH 5 PER CENT - 5-FLUOROURACIL (5-FU) CREAM
    HAYE, KR
    BRITISH JOURNAL OF VENEREAL DISEASES, 1974, 50 (06): : 466 - 466
  • [49] ALTERED PHARMACOKINETICS OF HIGH-DOSE 5-FLUOROURACIL (5-FU) WITH ALLOPURINOL (HPP) AND ANALYSIS OF ROUTES OF 5-FU ACTIVATION
    SCHWARTZ, PM
    HYDE, CM
    TUREK, PJ
    CADMAN, E
    HANDSCHUMACHER, RE
    PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, 1981, 22 (MAR): : 222 - 222
  • [50] ADJUVANT CHEMOTHERAPY WITH 5-FLUOROURACIL (5-FU) OR 5-FU PLUS METHYL-CCNU FOLLOWING SURGERY IN COLONIC CANCER
    DEXEUS, FA
    THIRLWELL, MP
    MACFARLANE, JK
    PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, 1978, 19 (MAR): : 367 - 367